Select therapeutic use:

Asthma/COPD:

Indications for: DUPIXENT

As an add-on maintenance treatment in patients with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Limitations of Use:

Not for relief of acute bronchospasm or status asthmaticus.

Adult Dosage:

Can use prefilled pens for patients ≥12yrs. Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. Initially 400mg (two 200mg inj at different sites) followed by 200mg every 2 weeks; or, initially 600mg (two 300mg inj at different sites) followed by 300mg every 2 weeks. For those with oral corticosteroid-dependent asthma or with co-morbid moderate to severe atopic dermatitis or co-morbid chronic rhinosinusitis with nasal polyposis: initially 600mg (two 300mg inj at different sites) followed by 300mg every 2 weeks.

Children Dosage:

<6yrs: not established. Can use prefilled pens for patients ≥12yrs. Initial loading dose is not recommended for patients 6–11yrs. Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. 6–11yrs (15–<30kg): 100mg every other week or 300mg every 4 weeks; (≥30kg): 200mg every other week. For those with asthma and co-morbid moderate to severe atopic dermatitis: follow dosage for atopic dermatitis which includes an initial loading dose.

DUPIXENT Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. New onset or worsening eye or joint symptoms; seek specialists if persist or worsen. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Update all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.

DUPIXENT Classification:

Interleukin-4 receptor alpha antagonist.

DUPIXENT Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringes (100mg, 200mg, 300mg)—2 (w. needle shield); Single-dose prefilled pens (200mg, 300mg)—2

Atopic dermatitis:

Indications for: DUPIXENT

Moderate to severe atopic dermatitis in patients who are not adequately controlled with topical prescription therapies or when they are not advisable.

Adults and Children:

<6 months: not established. Can use prefilled pens for patients ≥12yrs. Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. 6mos–5yrs (5–<15kg): 200mg every 4 weeks; (15–<30kg): 300mg every 4 weeks. 6–17yrs (15–<30kg): initially 600mg (two 300mg inj at different sites) followed by 300mg every 4 weeks; (30–<60kg): initially 400mg (two 200mg inj at different sites) followed by 200mg every other week; (≥60kg): initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. ≥18yrs: initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. May use with or without topical corticosteroids. Topical calcineurin inhibitors may also be used, but should be reserved only for problem areas (eg, face, neck, intertriginous and genital areas).

DUPIXENT Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. New onset or worsening eye or joint symptoms; seek specialists if persist or worsen. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Update all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.

DUPIXENT Classification:

Interleukin-4 receptor alpha antagonist.

DUPIXENT Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringes (100mg, 200mg, 300mg)—2 (w. needle shield); Single-dose prefilled pens (200mg, 300mg)—2

Miscellaneous dermatological conditions:

Miscellaneous gastrohepatic disorders:

Indications for: DUPIXENT

Eosinophilic esophagitis.

Adult Dosage:

Can use prefilled pens for patients ≥12yrs. Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. ≥12yrs (≥40kg): 300mg every week.

Children Dosage:

<12yrs (<40kg): not established.

DUPIXENT Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. New onset or worsening eye or joint symptoms; seek specialists if persist or worsen. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Update all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.

DUPIXENT Classification:

Interleukin-4 receptor alpha antagonist.

DUPIXENT Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringes (100mg, 200mg, 300mg)—2 (w. needle shield); Single-dose prefilled pens (200mg, 300mg)—2

Miscellaneous respiratory disorders:

Indications for: DUPIXENT

As an add-on maintenance treatment in patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Adult Dosage:

Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. ≥18yrs: 300mg every other week.

Children Dosage:

<18yrs: not established.

DUPIXENT Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. New onset or worsening eye or joint symptoms; seek specialists if persist or worsen. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Update all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.

DUPIXENT Classification:

Interleukin-4 receptor alpha antagonist.

DUPIXENT Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Drug Availability:

NO

How Supplied:

Single-dose prefilled syringes (100mg, 200mg, 300mg)—2 (w. needle shield); Single-dose prefilled pens (200mg, 300mg)—2